ArticleNeuro-oncology2004
Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials.
Article in Neuro-oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Loss of Heterozygosity of 9p Is Associated with Poorer Survival in Patients with Gliomas.Molecular neurobiology · 2016Pooled it
- Diagnosis of malignant glioma: role of neuropathology.Journal of neuro-oncology · 2008Guideline
- Proteogenomic characterization of skull-base chordoma.Nature communications · 2024Article
- SRSF4 Confers Temozolomide Resistance of Glioma via Accelerating Double Strand Break Repair.Journal of molecular neuroscience : MN · 2023Article
- Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma.Journal of neuro-oncology · 2020Article
- Article
- IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.Cancer science · 2018Article
- AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival.International journal of oncology · 2018Article
- Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.Acta neuropathologica communications · 2017Article
- Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.Brain pathology (Zurich, Switzerland) · 2016Article
- Article
- Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm.PloS one · 2015Article
- 1p/19q testing has no significance in the workup of glioblastomas.Neuropathology and applied neurobiology · 2013Article
- Correlation of histomorphologic prognostic markers and proliferative index with loss of heterozygosity 1p/19q and MGMT status in diffusely infiltrating gliomas.Medical journal, Armed Forces India · 2013Article
- Genetic and epigenetic alterations in primary-progressive paired oligodendroglial tumors.PloS one · 2013Article
- Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma.Molecular cancer research : MCR · 2012Article
- Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels.PloS one · 2012Article
- Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.The Journal of molecular diagnostics : JMD · 2011Article
- Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade.Brain pathology (Zurich, Switzerland) · 2011Review
- The pathobiology of glioma tumors.Annual review of pathology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Survival periods vary considerably for patients with high-grade astrocytomas, and reliable prognostic markers are not currently available. We therefore investigated whether genetic losses from chromosomes 1p, 19q, 9p, or 10q were associated with survival in 89 high-grade astrocytomas using tissue microarrays (TMAs) derived from Radiation Therapy Oncology Group clinical trials. Cases included 15 anaplastic astrocytomas (AAs) and 74 glioblastomas (GBMs) selected on the basis of survival times significantly shorter or longer than the expected median. Genetic analysis was performed by TMA-fluorescence in situ hybridization (FISH) on array sections using 8 DNA probes, including those directed at 1p32, 19q13.4, 9p21 (p16/CDKN2A), and 10q (PTEN and DMBT1). Genetic status for each locus was correlated with patient survival group, and data were analyzed by using Fisher's exact test of association (adjusted P = 0.025). Losses of chromosome 1p, either alone or in combination with 19q, were encountered in only 2 cases, both AAs. This contrasts with oligodendrogliomas, in which combined 1p and 19q losses are frequent and predictive of prolonged survival. Solitary 19q loss was noted in 3/15 AAs and in 7/70 GBMs and was more frequent in the long-term survival group (P = 0.041, AA and GBM combined). Chromosome 9p loss was seen in 5/8 AAs and 39/57 GBMs, whereas chromosome 10q loss was detected in 4/15 AAs and 48/68 GBMs. The 9p and 10q deletions were slightly more frequent in short-term survivors, though none of the comparisons achieved statistical significance. Long-term and short-term survival groups of high-grade astrocytomas appear to have dissimilar frequencies of 19q, 9p, and 10q deletions. TMA-FISH is a rapid and efficient way of evaluating genetic alterations in such tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.